INTERNATIONAL PATENT: INCYTE CORPORATION FILES APPLICATION FOR "COMBINATION THERAPY USING A KRAS G12D INHIBITOR AND A NUCLEOSIDE ANALOG AND/OR A MICROTUBULE INHIBITOR AND ITS USE IN THE TREATMENT OF CANCER"

GENEVA, May 6 -- INCYTE CORPORATION (1801 Augustine Cut-offWilmington, Delaware 19803) filed a patent application (PCT/US2025/052117) for "COMBINATION THERAPY USING A KRAS G12D INHIBITOR, AND A NUCLEOSIDE ANALOG, AND/OR A MICROTUBULE INHIBITOR AND ITS USE IN THE TREATMENT OF CANCER" on Oct 22, 2025. With publication no. WO/2026/090323, the details related to the patent application was published on Apr 30, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): FARREN, Matthew (c/o INCYTE CORPORATION1801 Augustine Cut-offWilmington, Delaware 19803), ROMAN, Valerie (c/o INCYTE CORPORATION1801 Augustin...